{"transactions":[{"id":1002315,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2508575,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Held directly by Pivotal bioVenture Partners Fund II, L.P. (\"Pivotal II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":294502},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002314,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":313571,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36812},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002313,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":313571,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":36812},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002312,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2104740,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":267367},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002311,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":1895260,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":240756},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002310,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":7230283,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":908821},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002309,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":2582243,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":324578},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002308,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":3572816,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":419441},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002307,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":false,"shares":7145647,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":838886},"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002306,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":294502,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Held directly by Pivotal bioVenture Partners Fund II, L.P. (\"Pivotal II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":294502,"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002305,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1632441,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP I\") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd (\"Pivotal GP II\"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited (\"NFIHL\"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":1632441,"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1002304,"issuer":{"id":5539,"kind":"organization","name":"Evommune, Inc."},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:46:56.000Z","date":"2025-11-07","kind":"exercise","planned":false,"acquired":true,"shares":1441032,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\") for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held directly by NFLS Delta III Limited (\"NFLS Delta\"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein."}],"balance_after":1441032,"source":{"system":"sec-edgar","filing":"0001012975-25-000730","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2044725/000101297525000730/form4.xml","form_type":"4"}},{"id":1816448,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T20:13:28.000Z","date":"2023-08-01","kind":"purchase","planned":false,"acquired":true,"shares":714285,"price":4.8,"value":3428568.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Pivotal I and Pivotal bioVenture Partners Fund II, L.P (\"Pivotal II\") is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited (\"NFIHL\"), which is wholly owned by Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by Pivotal II."}],"balance_after":1571741,"source":{"system":"sec-edgar","filing":"0000950170-23-038272","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000095017023038272/ownership.xml","form_type":"4"}},{"id":1816447,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-03T20:13:28.000Z","date":"2023-08-01","kind":"purchase","planned":false,"acquired":true,"shares":119048,"price":4.8,"value":571430.4,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held directly by Pivotal bioVenture Partners Fund I, L.P (\"Pivotal I\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The general partner of Pivotal I and Pivotal bioVenture Partners Fund II, L.P (\"Pivotal II\") is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited (\"NFIHL\"), which is wholly owned by Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein."}],"balance_after":2923110,"source":{"system":"sec-edgar","filing":"0000950170-23-038272","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000095017023038272/ownership.xml","form_type":"4"}},{"id":2293937,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-20T18:22:04.000Z","date":"2022-04-19","kind":"purchase","acquired":true,"shares":1070000,"price":3.69,"value":3948300.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd (\"Pivotal Partners\"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited (\"Pivotal Life Sciences\"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited (\"Nan Fung Life Sciences\"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited (\"NFIHL\"), which is wholly owned by Nan Fung Group Holdings Limited (\"NFGHL\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Mr. Kin Ho Kwok, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer.  Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein."}],"balance_after":2661154,"source":{"system":"sec-edgar","filing":"0001062993-22-010574","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000106299322010574/form4.xml","form_type":"4"}},{"id":3074915,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2020-07-28T18:15:06.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":10489510,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the securities owned by Pivotal. Such person's disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1403654},"source":{"system":"sec-edgar","filing":"0001012975-20-000664","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000101297520000664/edgar.xml","form_type":"4"}},{"id":3074914,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T18:15:06.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":187500,"price":16,"value":3000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the securities owned by Pivotal. Such person's disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein."}],"balance_after":1591154,"source":{"system":"sec-edgar","filing":"0001012975-20-000664","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000101297520000664/edgar.xml","form_type":"4"}},{"id":3074913,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-28T18:15:06.000Z","date":"2020-07-28","kind":"exercise","acquired":true,"shares":1403654,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the \"Ultimate General Partner\"). Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal's investment advisor and may be deemed to have shared voting and dispositive power over the securities owned by Pivotal. Such person's disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein."}],"balance_after":1403654,"source":{"system":"sec-edgar","filing":"0001012975-20-000664","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000101297520000664/edgar.xml","form_type":"4"}},{"id":3095322,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-01T16:14:36.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":1499971,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., or Pivotal GP. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1499971},"source":{"system":"sec-edgar","filing":"0001012975-20-000601","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000101297520000601/edgar.xml","form_type":"4"}},{"id":3095321,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T16:14:36.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":294117,"price":17,"value":4999989.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., or Pivotal GP. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal."}],"balance_after":1794088,"source":{"system":"sec-edgar","filing":"0001012975-20-000601","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000101297520000601/edgar.xml","form_type":"4"}},{"id":3095320,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-01T16:14:36.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":1499971,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P., or Pivotal GP. Robert Hopfner, Vincent Cheung, Peter Bisgaard, and Heather Preston are the managing partners of Pivotal and may be deemed to have shared voting and dispositive power over the shares owned by Pivotal."}],"balance_after":1499971,"source":{"system":"sec-edgar","filing":"0001012975-20-000601","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1722271/000101297520000601/edgar.xml","form_type":"4"}},{"id":3801605,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche B Convertible Preferred Stock","published_at":"2018-10-02T21:39:40.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":9502249,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\") is the general partner of Pivotal. Pivotal bioVenture Partners Fund I U.G.P., Ltd (\"Ultimate General Partner\") is the general partner of Pivotal GP. Richard Coles, Peter Bisgaard and Vincent Sai Sing Cheung are directors of the Ultimate General Partner and may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":458425},"source":{"system":"sec-edgar","filing":"0001209191-18-053537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000120919118053537/doc4.xml","form_type":"4"}},{"id":3801604,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Tranche A Convertible Preferred Stock","published_at":"2018-10-02T21:39:40.000Z","date":"2018-09-28","kind":"exercise","acquired":false,"shares":7446904,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\") is the general partner of Pivotal. Pivotal bioVenture Partners Fund I U.G.P., Ltd (\"Ultimate General Partner\") is the general partner of Pivotal GP. Richard Coles, Peter Bisgaard and Vincent Sai Sing Cheung are directors of the Ultimate General Partner and may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":359267},"source":{"system":"sec-edgar","filing":"0001209191-18-053537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000120919118053537/doc4.xml","form_type":"4"}},{"id":3801603,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:39:40.000Z","date":"2018-09-28","kind":"purchase","acquired":true,"shares":337724,"price":15,"value":5065860.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\") is the general partner of Pivotal. Pivotal bioVenture Partners Fund I U.G.P., Ltd (\"Ultimate General Partner\") is the general partner of Pivotal GP. Richard Coles, Peter Bisgaard and Vincent Sai Sing Cheung are directors of the Ultimate General Partner and may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal."}],"balance_after":1180178,"source":{"system":"sec-edgar","filing":"0001209191-18-053537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000120919118053537/doc4.xml","form_type":"4"}},{"id":3801602,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:39:40.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":458425,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\") is the general partner of Pivotal. Pivotal bioVenture Partners Fund I U.G.P., Ltd (\"Ultimate General Partner\") is the general partner of Pivotal GP. Richard Coles, Peter Bisgaard and Vincent Sai Sing Cheung are directors of the Ultimate General Partner and may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal."}],"balance_after":842454,"source":{"system":"sec-edgar","filing":"0001209191-18-053537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000120919118053537/doc4.xml","form_type":"4"}},{"id":3801601,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":73338,"kind":"person","name":"Pivotal bioVenture Partners Fund I, L.P.","position":1,"cik":"0001695076","reported_name":"Pivotal bioVenture Partners Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73339,"kind":"person","name":"Pivotal bioVenture Partners Fund I G.P., L.P.","position":2,"cik":"0001752862","reported_name":"Pivotal bioVenture Partners Fund I G.P., L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73340,"kind":"person","name":"Pivotal bioVenture Partners Fund I U.G.P. Ltd","position":3,"cik":"0001752847","reported_name":"Pivotal bioVenture Partners Fund I U.G.P., Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-02T21:39:40.000Z","date":"2018-09-28","kind":"exercise","acquired":true,"shares":359267,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the \"Preferred Stock\") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. (\"Pivotal\"). Pivotal bioVenture Partners Fund I G.P., L.P. (\"Pivotal GP\") is the general partner of Pivotal. Pivotal bioVenture Partners Fund I U.G.P., Ltd (\"Ultimate General Partner\") is the general partner of Pivotal GP. Richard Coles, Peter Bisgaard and Vincent Sai Sing Cheung are directors of the Ultimate General Partner and may, along with the Ultimate General Partner, be deemed to have shared voting and dispositive power over the shares owned by Pivotal."}],"balance_after":359267,"source":{"system":"sec-edgar","filing":"0001209191-18-053537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1695076/000120919118053537/doc4.xml","form_type":"4"}}]}